The virtual event will be held from February 24 to 26, 2021
The 6th edition of the India Pharmaceutical Forum, an annual flagship event hosted by the Indian Pharmaceutical Alliance, will be held virtually from February 24 to 26. The theme of 6th IPF is Patient Centricity: New Paradigm in Quality Management. It will focus on various aspects that define quality management in the pharmaceutical industry, in the post-COVID era, reinstating patient centricity as its focus.
The three-day conference will bring together dignitaries from the healthcare industry to express their views through discussions ensuing meaningful and actionable outcomes. The conference will commence with a keynote address by S Aparna, Secretary, Department of Pharmaceuticals, and the inauguration of IPA’s Best Practices document. Sessions will be held on varied topics under quality management including inspection during COVID-19 and GDUFA III Negotiation by David Gaugh, Senior Vice President for Sciences and Regulatory Affairs, AAM. An update on US FDA Quality Standard Control will be presented by Francis Godwin, Director, Office of Manufacturing Quality, Office of Compliance, US FDA.
The forum will also have panel discussions on contemporary subjects such as New Paradigm in Quality Management, Digitisation/Automation, and AI in operations and more. The last day will see a panel discussion comprising CEOs of leading Indian Pharma companies such as Cadila Healthcare, Cipla, Dr Reddy’s, Lupin, Sun Pharma, and Torrent Pharma to deliberate on ‘The impact of COVID-19 on pharmaceutical industry’.
Sudarshan Jain, Secretary-General, Indian Pharmaceutical Alliance said, “This year, the 6th Indian Pharmaceutical Forum will provide an engaging platform to facilitate a comprehensive discussion on the everchanging shift in quality management, led by significant voices of the industry. It will bring together relevant stakeholders from prominent organisations, leading pharma companies and regulatory bodies to discuss an action-oriented approach to operate in the future.”
Satish Reddy, President, Indian Pharmaceutical Alliance said, “The Indian pharmaceutical industry effectively rose to the challenges of COVID-19 and reinstated its potential in the global pharma landscape. Maintaining benchmark quality standards is pivotal for all Indian Pharmaceutical Alliance (IPA) member companies. IPA is committed towards driving excellence in quality and safety standards and the 6th Indian Pharmaceutical Forum (IPF) is a step ahead to showcase collaborative approach of the industry towards quality management while addressing evolving patient needs.”
